ED
QGENF

Exane Derivatives’s QIAGEN NV QGENF Stock Holding History

Exane Derivatives’s Portfolio QGENF Stock Details QGENF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-15,720
Closed -$442K – 719
2016
Q4 		$442K Buy
+15,720
New +$442K 0.09% 164

Other funds holding QGENF

BJCM
Blue Jay Capital Management Los Angeles, California $147M AUM 64.18% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital Fund Management (CFM)
Capital Fund Management (CFM) Paris, France $22.1B AUM 20.49% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $4.75B AUM 58.16% 1-Year Est. Return

Exane Derivatives's QGENF Position: Q1 2017 in Review

Exane Derivatives sold out of QIAGEN NV (QGENF) in Q1 2017, closing a stake of 15,720 shares — an estimated $442K sold.

Exane Derivatives first reported a position in QGENF in Q4 2016 and held it in 1 quarter. The position peaked at $442K in Q4 2016. 6 funds tracked by Wall St. Rank hold QGENF as of Q1 2017.

  • Exane Derivatives reported no remaining QIAGEN NV position as of Q1 2017 after selling out during the quarter.
  • Exane Derivatives sold 15,720 QIAGEN NV shares in Q1 2017, an estimated $442K.
  • Exane Derivatives first reported a position in QIAGEN NV in Q4 2016 and held it in 1 quarter.
  • Exane Derivatives's QIAGEN NV position peaked at $442K in Q4 2016.
  • 6 funds tracked by Wall St. Rank held QIAGEN NV as of Q1 2017.

Based on Exane Derivatives's 13F filing for Q1 2017, filed 28 Apr 2017.